Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib

NCT00644878 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

18

Enrollment

INDUSTRY

Sponsor class

Stopped Slower than expected enrollment

Conditions

Chronic Myelogenous Leukemia - Chronic Phase

Interventions

DRUG: Nilotinib

Sponsor

Novartis Pharmaceuticals